American Heart Association: March 2018
AHA Science News
Dr. Byron Lee, co-principal investigator of the VEST Trial, discusses results of LifeVest wearable cardioverter defibrillator use in low-EF, post-MI patients in this interview with Dr. Paul Wang, Editor-in-Chief of Circulation: Arrhythmia and Electrophysiology.
The VEST Trial (Vest Prevention of Early Sudden Death Trial) is a multi-center, randomized controlled trial of LifeVest use in patients who have recently suffered a heart attack (medically known as “post-myocardial infarction” or “post-MI”) and have a reduced heart function (medically known as a low “ejection fraction” or “EF” of 35 percent or less). Patients were randomized to receive LifeVest plus guideline-directed medical therapy (GDMT) or GDMT alone for 90 days following a heart attack.
LifeVest is a wearable cardioverter defibrillator (WCD) prescribed to patients at risk of sudden cardiac death (SCD), including those who have a reduced heart function following a heart attack or new diagnosis of heart failure.